US FDA approves use of carfilzomib in combination with daratumumab plus dexamethasone for the treatment of relapsed or refractory multiple myeloma

Two dosing regimens have been approved for use in patients who have received 1-3 previous lines of therapy. Approval was based on the CANDOR trial, which found a reduced risk of disease progression/death v carfilzomib plus dexamethasone (HR 0.63; 95% CI 0.464-0.854; p=0.0014).


Biospace Inc.